No defined molecular drug-like target

The term 'No defined molecular drug-like target' is a categorical placeholder used in pharmacological databases and clinical research to indicate that a specific molecular entity, such as a receptor, enzyme, or transporter, has not been identified as the primary site of action for a therapeutic agent. This classification is often applied to drugs with poorly characterized mechanisms, complex mixtures where the active moiety is unknown, or non-pharmacological interventions like placebos and physical therapies (Santos et al., 2017, Nature Reviews Drug Discovery). In the context of drug discovery, this label signifies that the therapeutic effect cannot be attributed to a discrete, druggable biological molecule, making standard metrics like binding affinity or structure-based design inapplicable (Overington et al., 2006, Nature Reviews Drug Discovery). For biotech analysts, this designation highlights a significant gap in mechanistic understanding, which may present challenges for regulatory approval and the development of targeted second-generation therapies. It essentially serves as a 'catch-all' for interventions that lack a validated molecular point of contact within the human interactome.

Other names

Unknown targetNon-specific targetTarget not yet identifiedUnassigned targetNon-molecular target

The mechanism of action is unknown, non-specific, or not mediated through a traditional molecular drug target such as a protein or nucleic acid.